|
|
| Product Name: | JNJ 1661010 | | Synonyms: | JNJ 1661010;N-Phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)-1-piperazinecarboxamide;Takeda-25;JNJ 1661010, >=98%;CS-1527;N-Phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide;TAKEDA-25;JNJ-1661010;JNJ 1661010;JNJ 1661010 USP/EP/BP | | CAS: | 681136-29-8 | | MF: | C19H19N5OS | | MW: | 365.45 | | EINECS: | | | Product Categories: | Inhibitors;Inhibitor | | Mol File: | 681136-29-8.mol |  |
| | JNJ 1661010 Chemical Properties |
| density | 1.340±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,2-8°C | | solubility | DMSO: ≥28mg/mL | | form | solid | | pka | 13.94±0.70(Predicted) | | color | Off-white | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. |
| | JNJ 1661010 Usage And Synthesis |
| Solubility | JNJ 1661010 is soluble to 100 mM in DMSO and to 10 mM in ethanol. | | Description | JNJ-1661010 (681136-29-8) is a potent and selective FAAH inhibitor. Initially forms a covalent adduct with FAAH but is slowly released, IC50 = 12 nM. 100-fold selectivity for FAAH-1 over FAAH-2. Cell permeable and active in vivo. JNJ-1661010 displays analgesic activity in various animal models. | | Uses | JNJ-1661010, is used to examine the contribution of endocannabinoid signaling in experimental fibrosis. In biological studies, this compound had shown to elevate the levels of arachidonoyl ethanolamide (AEA) in rat brains. | | Definition | ChEBI: JNJ-1661010 is a N-arylpiperazine. | | Biological Activity | Selective, reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC 50 = 12nM). Brain penetrant and active in vivo . | | storage | Store at +4°C | | References | 1) Karbarz et al. (2009), Biochemical and biological properties of 4-(3-phenyl-[1,2,4]thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase; Anesth. Analg., 108 316 |
| | JNJ 1661010 Preparation Products And Raw materials |
|